autoimmune

Poster Days Spotlight Young Researchers

Budding Scientists Showcase Research at Annual Event

Yasmin Ali

Any scientist who wants to make game-changing discoveries has to start somewhere — even Albert Einstein worked in a patent office before landing his first job in academia. Through its Postbaccalaureate IRTA program, NIH hopes to give aspiring scientists more of a leg up than Einstein had by bringing them into IRP labs after they complete their undergraduate studies.

On April 26, 27, and 28, more than 900 recent college graduates participating in the program presented at this year’s virtual Postbac Poster Days. Read on to learn about a few of these young researchers and their contributions to the groundbreaking work being done at NIH.

IRP Scientists Continue Efforts to Quell Pandemic

COVID-19 Research at NIH Show No Signs of Slowing

SARS-CoV-2 virus particle

It’s been more than two years since the first outbreak of COVID-19 occurred in China. During that time, amazing scientific advances have dramatically altered prevention and treatment for the illness, including the development of remarkably safe and effective vaccines. However, even with widespread vaccination, scientists predict that the disease will continue to circulate in society indefinitely, with seasonal ebbs and flows like the flu.

As a result, even as COVID-19 vaccine shots rolled out by the hundreds of millions, numerous IRP researchers continued studying the disease and the virus responsible for it. Many of these projects have been funded by the NIH’s Intramural Targeted Anti-COVID-19 Program (ITAC), an initiative that provides IRP researchers with funding for research related to COVID-19. Over the past year and a half, ITAC has provided more than $12 million to support a wide variety of projects — more than can be covered in just one blog post. Read on to learn about just a handful of the many ways IRP researchers are contributing to the fight against COVID-19, and stay tuned next week for another blog describing even more ITAC-funded COVID research.

Genetic Sequencing Solves Drug Reaction Mystery

Immune System Genes Linked to Severe Side Effects in Patients with Rare Disease

computer monitor showing the results of DNA sequencing

When you run the largest-ever study of a rare childhood disease, you become the go-to person when your peers notice something peculiar in patients with the illness. It was not too surprising, then, when a researcher from Stanford University in Palo Alto, California, asked IRP investigator Michael Ombrello, M.D., to help her team follow a new lead in the mystery of why some patients with a rare inflammatory condition called Still’s disease were coming down with a life-threatening lung ailment. The results of their collaboration could lead to a new precision medicine approach that individualizes therapy for Still’s disease based on patients’ DNA.

A Sweet Treatment for Diabetes

Sugar Molecule Protects Mice Against Type 1 Diabetes

a spoonful of sugar

Avoiding too much sugar is one of the cardinal rules for those who have or are at risk for diabetes. In fact, diabetes is characterized by having too much glucose, a form of sugar, in the blood. As a result, it came as quite a surprise to IRP researchers led by senior investigator Wanjun Chen, M.D., when they discovered that a particular form of sugar that they expected to have no effect on diabetes-prone mice actually protected them from developing type 1 diabetes.

Medical Research Scholars Reflect on Their NIH Journeys

Future Physician-Scientists Spent a Year in IRP Labs

MRSP participant working in the lab

Many doctors not only treat patients directly, but also make valuable contributions to research that will improve medical care in the future. Each one of these talented ‘physician-scientists’ began his or her research career under the guidance of a more senior scientist. At the NIH, the Medical Research Scholars Program (MRSP) provides just such an experience to promising young medical students from all across the United States.

Innovation Awards Spark New Intramural Collaborations

Program Boosts Initiatives Supporting Researchers Across NIH

scientists talking in a lab

From Superbowl-winning football teams to comic book cohorts like The Avengers, combining the efforts of multiple talented individuals is a proven strategy for achieving remarkable results. It may come as no surprise, then, that the NIH’s Intramural Research Program (IRP) strongly encourages collaborations that breach the boundaries of its 24 Institutes and Centers. One example of these efforts is the Director’s Challenge Innovation Awards Program, which since 2009 has funded high-impact scientific projects that bring together researchers from across the IRP.

Immune Cells Produce Potent Packages of Anti-Inflammatory Molecule

Experimental Treatment Curbs Autoimmune Eye Disease in Mice

B cell

Our cells produce a wide range of chemicals necessary for good health, but when they cannot manufacture enough of these substances, scientists can use cells cultivated in their labs to pick up the slack. In a promising example of this approach, IRP scientists stimulated lab-grown immune cells to produce tiny bundles of an important anti-inflammatory molecule and used those packages to successfully treat a potentially blinding autoimmune disease in mice.

IRP’s Luigi Notarangelo Elected to National Academy of Medicine

NIH Researcher Recognized for Insights into Genetic Immune System Diseases

Dr. Luigi Notarangelo

The National Academy of Medicine (NAM), first established in 1970 by the National Academy of Sciences as the Institute of Medicine (IOM), is comprised of more than 2,000 elected members from around the world who provide scientific and policy guidance on important matters relating to human health. Election to the NAM is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have not only made critical scientific discoveries but have also demonstrated a laudable commitment to public service.

IRP senior investigator Luigi Notarangelo, M.D., was one of four IRP researchers recently elected to the NAM. As the head of the Immune Deficiency Genetics Section and the Laboratory of Clinical Immunology and Microbiology at the National Institute of Allergy and Infectious Diseases (NIAID), Dr. Notarangelo investigates the cellular and molecular roots of genetic conditions called primary immune deficiencies that compromise the immune system. These illnesses leave patients — many of whom are children — highly vulnerable to infections and can also lead to autoimmune problems caused when the immune system attacks the body’s own tissues. Some of Dr. Notarangelo’s patients have known genetic mutations, while for others the source of their disease remains a mystery.

Cellular Therapy Could Soothe Sarcoidosis

Cells From Bone Marrow Calm Damaging Immune Response

cells

In patients with the inflammatory disease sarcoidosis, the body’s own immune cells rampage around the body like The Incredible Hulk set loose in a city, attacking both harmful pathogens and our own tissues. However, just like the Black Widow can calm The Hulk down and return him to human form in the Avengers films, cells isolated from our bone marrow may be able to change certain immune cells from a damaging state to a benign one, according to new IRP research.

Scientists Pinpoint Traitorous Immune Cells in Lupus

Narrower Research Focus Could Aid Treatment for Autoimmune Diseases

immune cells called neutrophils (purple) attacking bacteria

Police pursuing a dangerous criminal rely on witness descriptions of the suspect’s specific traits — height, weight, hair color, tattoos — to pick out the perpetrator from a vast population of mostly innocent individuals. Scientists can likewise distinguish between highly similar cell types using cutting-edge laboratory procedures. Using such techniques, IRP researchers have identified a particular variety of cell in a specific stage of its life cycle as a primary culprit behind the autoimmune disease known as lupus.